地龙提取物减轻炎症缓解斑马鱼血栓形成

doi:10.3976/j.issn.1002-4026.2025068

摘要/Abstract

摘要： 本研究基于斑马鱼模型研究地龙提取物（Pheretimaextract,Phe）抗血栓活性及作用机制。实验利用普纳替尼(Ponatinib,PON)诱导的斑马鱼血栓模型，评价地龙提取抗血栓活性，测定心率、血流速度；使用血小板荧光标记品系Tg(CD41:eGFP)斑马鱼测定斑马鱼体内循环血小板的数量，使用巨噬细胞标记品系Tg(coro1a:EGFP)斑马鱼检测地龙提取物对斑马鱼体内炎症反应的影响，并利用qRT-PCR检测地龙提取物对相关靶点表达的影响。发现地龙提取物能显著改善普纳替尼诱导的斑马鱼血栓模型的多项病理指标：有效提升因药物导致的心率下降，改善尾部血流速度，并减轻炎症反应，同时减少循环血小板的消耗。进一步的实时荧光定量聚合酶链式反应（qPCR）分析显示，地龙提取物作为芪龙胶囊的主要药效成分，能够有效抑制普纳替尼诱导的多种凝血相关基因（VWF、f2、fga、fgb、tbxas1）及炎症相关因子/基因及通路（NF-κB、IL-1β）的上调表达。表明了地龙提取物可能通过调控凝血级联反应，抑制血小板活化和聚集和抑制炎症反应发挥抗血栓作用。

关键词: 斑马鱼模型, 血栓形成, 地龙提取物, 炎症缓解

Abstract: This study investigated the anti-thrombotic activity and underlying mechanisms of action of pheretima extract (Phe) based on a zebrafish model. A Ponatinib (PON)-induced zebrafish thrombosis model was used to evaluate the anti-thrombotic activity of Phe by measuring heart rate and blood flow velocity. The transgenic zebrafish line Tg(CD41:eGFP), with fluorescently labeled platelets, was used to quantify circulating platelets in vivo, while the macrophage-labeled transgenic line Tg(coro1a:EGFP) was used to assess the effects of Phe on inflammatory responses. In addition, quantitative real-time PCR (qRT-PCR) was used to examine the impact of the Phe on the expression of related target genes. The results showed that Phe significantly improved multiple pathological indicators in the PON-induced zebrafish thrombosis model: it effectively restored drug-induced reductions in heart rate, improved tail blood flow velocity, alleviated inflammatory responses, and reduced the consumption of circulating platelets. Further quantitative PCR (qPCR) analysis indicated that Phe, as the primary active component of Qilong capsules, effectively inhibited the upregulation of multiple coagulation- (VWF, f2, fga, fgb, and tbxas1) and inflammation-related genes (NF-κB and IL-1β) induced by PON. These findings suggest that Phe might exert anti-thrombotic effects by regulating the coagulation cascade, inhibiting platelet activation and aggregation, and suppressing inflammatory response.

Key words: zebrafish model, thrombosis, pheretima extract, inflammation relief

中图分类号:

R965.1

陈佳瑜, 高松英, 展文, 杜兴硕, 李晓彬, 夏青, 何秋霞. 地龙提取物减轻炎症缓解斑马鱼血栓形成[J]. 山东科学, 0, (): 1-.

CHEN Jiayu, GAO Songying, ZHAN Wen, DU Xingshuo, LI Xiaobin, XIA Qing, HE Qiuxia. Pheretimextract relieves inflammation and thrombosis in zebrafish[J]. Shandong Science, 0, (): 1-.

参考文献

[1] FEIGIN V L, STARK B A, JOHNSON C O, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. The Lancet Neurology, 2021, 20(10): 795-820. DOI:10.1016/S1474-4422(21)00252-0

[2]CHEN X, ZHAO X, COOPER M, et al. The Roles of GRKs in Hemostasis and Thrombosis [J].International journal of molecular sciences, 2020, 21(15).

[3]王志飞,谢颖桢,谢雁鸣,等.芪龙胶囊临床应用专家共识[J].中国中药杂志, 2019, 44(24): 5287-5290. DOI:10.19540/j.cnki.cjcmm.20191105.503.

[4]魏玮.地龙蛋白肽的分离纯化、结构鉴定及抗血栓活性研究[D].镇江:江苏大学, 2022.

[5]陈卫宁,杨甲强.复方地龙片联合注射用血塞通治疗急性缺血性脑卒中的临床效果[J].临床医学研究与实践, 2021, 6(30): 131-133. DOI:10.19347/j.cnki.2096-1413.202130043.

[6]赵天旸.地龙提取物中成分分析及抗凝血溶栓功效研究[D].天津:天津科技大学, 2024.

[7] COTTER T G, PILLAI A A. Consult for portal vein thrombosis[J]. Clinical Liver Disease, 2019, 14(2): 74-77. DOI:10.1002/cld.748.

[8]汪海英,蒋虎刚,王新强,等.地龙的临床应用及药理作用的研究进展[J].实用中医内科杂志, 2024, 38(12): 92-95. DOI:10.13729/j.issn.1671-7813.Z20240011.

[9]莫彩莲,李杰,王加珍,等.斑马鱼血栓模型在中药活性成分筛选中的适用性[J].山东科学, 2021, 34(4): 52-59.

[10] QI Y Q, ZHAO X P, LIU H, et al.Identification of a quality marker (Q-marker) of Danhong injection by the zebrafish thrombosis model[J].Molecules, 2017, 22(9): 1443. DOI:10.3390/molecules22091443.

[11] LOREN C P, ASLAN J E, RIGG R A, et al.The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear[J]. Thrombosis Research, 2015, 135(1): 155-160. DOI:10.1016/j.thromres.2014.11.009.

[12] WANG X, CHEN R J, LIU J L, et al. Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: A pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database[J]. Expert Opinion on Drug Safety, 2025: 1-9. DOI:10.1080/14740338.2025.2460449.

[13] MEZEI G, BATÁR P, KOZMA L, et al. Ponatinib exerts an inhibitory effect on collagen-induced platelet aggregation and generation of coated-platelets[J]. Anticancer Research, 2021, 41(10): 4867-4874. DOI:10.21873/anticanres.15300.

[14] AMIN S O, RUZICKA M, BURNS K D, et al. Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib[J]. The Journal of Clinical Hypertension, 2020, 22(4): 678-682. DOI:10.1111/jch.13843.

[15] PARKER T, LIBOUREL P A, HETHERIDGE M J, et al. A multi-endpointin vivolarval zebrafish (Danio rerio) model for the assessment of integrated cardiovascular function[J]. Journal of Pharmacological and Toxicological Methods, 2014, 69(1): 30-38. DOI:10.1016/j.vascn.2013.10.002.

[16] MERKULOVA A, MITCHELL S C, STAVROU E X, et al. Ponatinib treatment promotes arterial thrombosis and hyperactive platelets[J]. Blood Advances, 2019, 3(15): 2312-2316. DOI:10.1182/bloodadvances.2019000034.

[17] KATTOOR A J, POTHINENI N V K, PALAGIRI D, et al. Oxidative stress in atherosclerosis[J]. Current Atherosclerosis Reports, 2017, 19(11): 42. DOI:10.1007/s11883-017-0678-6.

[18]刘旭,万鹏飞,杨维佳,等. PDE2A通过影响脉络膜血管生成和NADPH氧化酶/ROS/NF-κB通路参与年龄相关性黄斑变性[J].现代生物医学进展, 2023, 23(6): 1033-1040.DOI:10.13241/j.cnki.pmb.2023.06.007.

[19] MITTAL M, SIDDIQUI M R, TRAN K, et al.Reactive oxygen species in inflammation and tissue injury[J]. Antioxidants & Redox Signaling, 2014, 20(7): 1126-1167. DOI:10.1089/ars.2012.5149.

[20] TALL A R, BORNFELDT K E. Inflammasomes and atherosclerosis: A mixed picture[J]. Circulation Research, 2023, 132(11): 1505-1520. DOI:10.1161/CIRCRESAHA.123.321637.

[21] GREBE A, HOSS F, LATZ E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis[J]. Circulation Research, 2018, 122(12): 1722-1740. DOI:10.1161/CIRCRESAHA.118.311362.

[22] RIDKER P M, RANE M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J]. Circulation Research, 2021, 128(11): 1728-1746. DOI:10.1161/CIRCRESAHA.121.319077.

[23] DONG Z J, ZHUO R, WANG Q, et al. Kif15 regulates Coro1a+ cell migration and phagocytosis in zebrafish after spinal cord injury[J].International Immunopharmacology, 2025, 146: 113874. DOI:10.1016/j.intimp.2024.113874.

[24] HUANG B N, TANG P, LIU Y C, et al.Xuefu Zhuyu decoction alleviates deep vein thrombosis through inhibiting the activation of platelets and neutrophilsviasirtuin 1/nuclear factor kappa-B pathway[J]. Journal of Ethnopharmacology, 2024, 333: 118485. DOI:10.1016/j.jep.2024.118485.

[25] MEHTA D, MALIK A B. Signaling mechanisms regulating endothelial permeability[J]. Physiological Reviews, 2006, 86(1): 279-367. DOI:10.1152/physrev.00012.2005.

[26] GROSS P L, AIRD W C. The endothelium and thrombosis[J]. Seminars in Thrombosis and Hemostasis, 2000, 26(5): 463-478.DOI:10.1055/s-2000-13202.

[27] BROOS K, FEYS H B, DE MEYER S F, et al. Platelets at work in primary hemostasis[J]. Blood Reviews, 2011, 25(4): 155-167. DOI:10.1016/j.blre.2011.03.002.

[28] WEI Z C, ZUO F, WANG W Q, et al. Protective effects of total flavones ofElaeagnus rhamnoides(L.) A. nelson against vascular endothelial injury in blood stasis model rats[J]. Evidence-Based Complementary and Alternative Medicine, 2017, 2017: 8142562. DOI:10.1155/2017/8142562.

[29] WEISEL J W, LITVINOV R I. Red blood cells: The forgotten player in hemostasis and thrombosis[J]. Journal of Thrombosis and Haemostasis, 2019, 17(2): 271-282. DOI:10.1111/jth.14360.

[30] ZHOU Z Y, HUAN L Y, ZHAO W R, et al. Spatholobi Caulis extracts promote angiogenesis in HUVECsin vitroand in zebrafish embryosin vivoviaup-regulation of VEGFRs[J]. Journal of Ethnopharmacology, 2017, 200: 74-83. DOI:10.1016/j.jep.2016.10.075.

[31] MORRELL C N, HILT Z T, PARISER D N, et al. PAD4 and von willebrand factor link inflammation and thrombosis[J]. Circulation Research, 2019, 125(5): 520-522. DOI:10.1161/CIRCRESAHA.119.315601.

[32] VO A H, SWAROOP A, LIU Y, et al. Loss of fibrinogen in zebrafish results in symptoms consistent with human hypofibrinogenemia[J]. PLoS One, 2013, 8(9): e74682. DOI:10.1371/journal.pone.0074682.

[33] KIM K A, CHOI S Y, KIM R. Endovascular treatment for lower extremity deep vein thrombosis: An overview[J]. Korean Journal of Radiology, 2021, 22(6): 931-943. DOI:10.3348/kjr.2020.0675.

[34] LIN S H, LIU X, SUN A N, et al. Qilong capsule alleviates ponatinib-induced ischemic stroke in a zebrafish model by regulating coagulation, inflammation and apoptosis[J]. Journal of Ethnopharmacology, 2023, 314: 116397. DOI:10.1016/j.jep.2023.116397.

[35] LIU X, FAN W, LIN S H, et al. Anti-thrombotic effect of protoparaxotriol saponins fromPanax notoginsengusing zebrafish model[J]. Journal of Cardiovascular Pharmacology, 2024, 84(5): 528-538. DOI:10.1097/FJC.0000000000001604.